Open AccessACTR-38. A PHASE I TRIAL OF AFATINIB AND RADIOTHERAPY (RT) WITH OR WITHOUT TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Author(s) -
Frank Saran,
Allan James,
Catherine McBain,
Sarah Jefferies,
Fiona Harris,
A. Cseh,
Karine Pemberton,
Jennifer Schaible,
Shaun Bender,
Michael Brada
Publication year - 2018
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/noy148.071
Subject(s) - afatinib , medicine , regimen , clinical endpoint , rash , nausea , adverse effect , temozolomide , gastroenterology , oncology , radiation therapy , clinical trial , cancer , epidermal growth factor receptor , gefitinib
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom